Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 24

1.

Relationship between treatment effects on progression-free survival and overall survival in multiple myeloma: a systematic review and meta-analysis of published clinical trial data.

Cartier S, Zhang B, Rosen VM, Zarotsky V, Bartlett JB, Mukhopadhyay P, Wagner S, Davis C.

Oncol Res Treat. 2015;38(3):88-94. doi: 10.1159/000375392. Epub 2015 Feb 20. Review.

PMID:
25792079
2.

Lenalidomide enhances the anti-prostate cancer activity of docetaxel in vitro and in vivo.

Henry JY, Lu L, Adams M, Meyer B, Bartlett JB, Dalgleish AG, Galustian C.

Prostate. 2012 Jun 1;72(8):856-67. doi: 10.1002/pros.21488. Epub 2011 Oct 3.

PMID:
21968939
3.

Lenalidomide downregulates the cell survival factor, interferon regulatory factor-4, providing a potential mechanistic link for predicting response.

Lopez-Girona A, Heintel D, Zhang LH, Mendy D, Gaidarova S, Brady H, Bartlett JB, Schafer PH, Schreder M, Bolomsky A, Hilgarth B, Zojer N, Gisslinger H, Ludwig H, Daniel T, J├Ąger U, Chopra R.

Br J Haematol. 2011 Aug;154(3):325-36. doi: 10.1111/j.1365-2141.2011.08689.x. Epub 2011 Jun 24.

PMID:
21707574
4.

Lenalidomide enhances antibody-dependent cellular cytotoxicity of solid tumor cells in vitro: influence of host immune and tumor markers.

Wu L, Parton A, Lu L, Adams M, Schafer P, Bartlett JB.

Cancer Immunol Immunother. 2011 Jan;60(1):61-73. doi: 10.1007/s00262-010-0919-9. Epub 2010 Sep 17.

PMID:
20848094
5.

Dexamethasone synergizes with lenalidomide to inhibit multiple myeloma tumor growth, but reduces lenalidomide-induced immunomodulation of T and NK cell function.

Gandhi AK, Kang J, Capone L, Parton A, Wu L, Zhang LH, Mendy D, Lopez-Girona A, Tran T, Sapinoso L, Fang W, Xu S, Hampton G, Bartlett JB, Schafer P.

Curr Cancer Drug Targets. 2010 Mar;10(2):155-67.

PMID:
20088798
6.

Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis.

Schafer PH, Parton A, Gandhi AK, Capone L, Adams M, Wu L, Bartlett JB, Loveland MA, Gilhar A, Cheung YF, Baillie GS, Houslay MD, Man HW, Muller GW, Stirling DI.

Br J Pharmacol. 2010 Feb;159(4):842-55. doi: 10.1111/j.1476-5381.2009.00559.x. Epub 2009 Dec 24.

7.

Inhibition of metastatic potential in colorectal carcinoma in vivo and in vitro using immunomodulatory drugs (IMiDs).

Liu WM, Henry JY, Meyer B, Bartlett JB, Dalgleish AG, Galustian C.

Br J Cancer. 2009 Sep 1;101(5):803-12. doi: 10.1038/sj.bjc.6605206. Epub 2009 Jul 28.

8.

Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivo.

Zhang L, Qian Z, Cai Z, Sun L, Wang H, Bartlett JB, Yi Q, Wang M.

Am J Hematol. 2009 Sep;84(9):553-9. doi: 10.1002/ajh.21468.

9.

Antiproliferative effects of CC-8062 and CC-8075 in pancreatic cancer cells.

Mouratidis PX, Colston KW, Bartlett JB, Muller GW, Man HW, Stirling D, Dalgleish AG.

Pancreas. 2009 Jan;38(1):78-84.

PMID:
19117086
10.

The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells.

Galustian C, Meyer B, Labarthe MC, Dredge K, Klaschka D, Henry J, Todryk S, Chen R, Muller G, Stirling D, Schafer P, Bartlett JB, Dalgleish AG.

Cancer Immunol Immunother. 2009 Jul;58(7):1033-45. doi: 10.1007/s00262-008-0620-4. Epub 2008 Nov 14.

PMID:
19009291
11.

The anti-cancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endothelial cell function in normoxic and hypoxic conditions.

Lu L, Payvandi F, Wu L, Zhang LH, Hariri RJ, Man HW, Chen RS, Muller GW, Hughes CC, Stirling DI, Schafer PH, Bartlett JB.

Microvasc Res. 2009 Mar;77(2):78-86. doi: 10.1016/j.mvr.2008.08.003. Epub 2008 Sep 4.

PMID:
18805433
12.

lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells.

Wu L, Adams M, Carter T, Chen R, Muller G, Stirling D, Schafer P, Bartlett JB.

Clin Cancer Res. 2008 Jul 15;14(14):4650-7. doi: 10.1158/1078-0432.CCR-07-4405.

13.

An assessment of the in vivo efficacy of the glycogen phosphorylase inhibitor GPi688 in rat models of hyperglycaemia.

Poucher SM, Freeman S, Loxham SJ, Convey G, Bartlett JB, De Schoolmeester J, Teague J, Walker M, Turnbull AV, Charles AD, Carey F, Berg S.

Br J Pharmacol. 2007 Dec;152(8):1239-47. Epub 2007 Oct 15.

14.

Sensitivity of glycogen phosphorylase isoforms to indole site inhibitors is markedly dependent on the activation state of the enzyme.

Freeman S, Bartlett JB, Convey G, Hardern I, Teague JL, Loxham SJ, Allen JM, Poucher SM, Charles AD.

Br J Pharmacol. 2006 Nov;149(6):775-85. Epub 2006 Oct 3.

15.

The correlation between colorectal cancer rates of proliferation and apoptosis and systemic cytokine levels; plus their influence upon survival.

Evans C, Morrison I, Heriot AG, Bartlett JB, Finlayson C, Dalgleish AG, Kumar D.

Br J Cancer. 2006 May 22;94(10):1412-9.

16.

The synthetic compound CC-5079 is a potent inhibitor of tubulin polymerization and tumor necrosis factor-alpha production with antitumor activity.

Zhang LH, Wu L, Raymon HK, Chen RS, Corral L, Shirley MA, Narla RK, Gamez J, Muller GW, Stirling DI, Bartlett JB, Schafer PH, Payvandi F.

Cancer Res. 2006 Jan 15;66(2):951-9.

17.

Recent clinical studies of the immunomodulatory drug (IMiD) lenalidomide.

Bartlett JB, Tozer A, Stirling D, Zeldis JB.

Br J Cancer. 2005 Sep 19;93(6):613-9. Review.

18.

Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro.

Dredge K, Horsfall R, Robinson SP, Zhang LH, Lu L, Tang Y, Shirley MA, Muller G, Schafer P, Stirling D, Dalgleish AG, Bartlett JB.

Microvasc Res. 2005 Jan;69(1-2):56-63.

PMID:
15797261
19.

Thalidomide-derived immunomodulatory drugs as therapeutic agents.

Galustian C, Labarthe MC, Bartlett JB, Dalgleish AG.

Expert Opin Biol Ther. 2004 Dec;4(12):1963-70. Review.

PMID:
15571458
20.

Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma.

Schey SA, Fields P, Bartlett JB, Clarke IA, Ashan G, Knight RD, Streetly M, Dalgleish AG.

J Clin Oncol. 2004 Aug 15;22(16):3269-76. Epub 2004 Jul 12.

PMID:
15249589
21.

The evolution of thalidomide and its IMiD derivatives as anticancer agents.

Bartlett JB, Dredge K, Dalgleish AG.

Nat Rev Cancer. 2004 Apr;4(4):314-22. doi: 10.1038/nrc1323. Review. No abstract available.

PMID:
15057291
22.

Phase I study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers.

Bartlett JB, Michael A, Clarke IA, Dredge K, Nicholson S, Kristeleit H, Polychronis A, Pandha H, Muller GW, Stirling DI, Zeldis J, Dalgleish AG.

Br J Cancer. 2004 Mar 8;90(5):955-61.

23.

Neutralization of Clostridium difficile toxin by Clostridium sordellii antitoxins.

Chang TW, Gorbach SL, Bartlett JB.

Infect Immun. 1978 Nov;22(2):418-22.

24.

1-chloro-2,4-dinitrobenzene as an algicide. Report of four cases of contact dermatitis.

Adams RM, Zimmerman MC, Bartlett JB, Preston JF.

Arch Dermatol. 1971 Feb;103(2):191-3. No abstract available.

PMID:
4251762

Supplemental Content

Loading ...
Support Center